FDA Orange Book
Generic for Ovide
Ovide contains malathion. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
Yes. The generic name for Ovide is malathion. 1 company holds an active FDA approval (ANDA) for a generic version in the Orange Book.
Run it in Rivvi
Map Ovide and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Ovide products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| lotion, topical | 0.5% | Discontinued | None | 1 | None |
NDA 018613, held by TARO PHARMACEUTICAL INDUSTRIES LTD. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Approved generic malathion
| Company | ANDA | TE code | Approved | Strengths |
|---|---|---|---|---|
| COHANCE LIFESCIENCES LTD | 091559 | None (No TE code listed) | May 23, 2012 | 0.5% |
Ovide patents
| Patent | Expires | Covers | Use code | NDA |
|---|---|---|---|---|
| 7977324 | August 14, 2026 | Drug product | None | 018613 |
| 7560445 | February 1, 2027 | Drug substance, Drug product | U-986 | 018613 |
Questions
Is there a generic for Ovide?
Yes. The generic name for Ovide is malathion. 1 company holds an active FDA approval (ANDA) for a generic version in the Orange Book.
What is the generic name for Ovide?
The active ingredient in Ovide is malathion, per the FDA Orange Book.
When does the Ovide patent expire?
The last patent listed for Ovide in the Orange Book expires February 1, 2027. A listed patent expiry date is not a generic launch date.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.